A treatment specifically for HER2-positive metastatic breast cancer

PERJETA is a targeted therapy for treating HER2-positive metastatic breast cancer.

Targeted therapies are designed to search for and attack specific parts of the cancer cell that cause it to grow and multiply. A few therapies have been developed to target the HER2 receptor. These targeted therapies, such as PERJETA and Herceptin (trastuzumab), aim to fight cancer cells that have too much HER2, and are designed to cause less harm to healthy cells. Since healthy cells also have HER2 (just not as much), HER2-targeted therapies can also affect healthy cells, which may cause side effects, some of which can be serious. PERJETA is a targeted therapy, like Herceptin, but it works to fight cancer in a different way.

PERJETA was designed to search for and attack cancer cells with too much HER2

HER2 tells cancer cells to grow by sending signals

 

PERJETA was designed to search for and attack Cancer Cells

    • HER2 works by sending signals that tell cells to grow and divide
    • One way that HER2 can send signals is by pairing with other HER receptors. This process is called dimerization

What are the most serious side effects of PERJETA?

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

Please refer to the full Prescribing Information for more information on these serious side effects.

PERJETA works with Herceptin to target HER2

 

PERJETA works with Herceptin to target HER2

    • PERJETA and Herceptin both target HER2 but work in different ways
    • PERJETA is thought to block one method of signaling so that certain receptors are unable to pair (dimerization) with HER2
    • Together, PERJETA and Herceptin are thought to create a stronger blockade against HER2 signals, helping to slow down cancer cell growth

Stopping HER2 signaling could inhibit the growth of tumors.

What does PERJETA treat?

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Important Safety Information

What should I know about side effects with PERJETA?

  • Not all people have serious side effects; however, side effects with PERJETA therapy are common. It is important to know what side effects may happen and what symptoms you should watch for
  • Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects

What are the most serious side effects?

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

  • Your doctor may run tests to monitor your heart function before and during treatment with PERJETA
  • Based on test results your doctor may hold or discontinue treatment with PERJETA

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

  • Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com and report PERJETA exposure to Genentech at 1-888-835-2555

What are other possible serious side effects?

  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Infusion-related reactions: PERJETA is a medicine that is delivered into a vein through a needle. This process can cause reactions known as infusion-related reactions. The most common infusion-related reactions when receiving PERJETA, Herceptin, and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain, and vomiting. The most common infusion-related reactions when receiving PERJETA alone were fever, chills, feeling tired, headache, weakness, allergic reactions, and vomiting
  • Severe allergic reactions: Some people receiving PERJETA may have severe allergic reactions, called hypersensitivity reactions or anaphylaxis. This reaction may be severe, may happen quickly, and may affect many areas of the body

How will my doctor and I know if PERJETA is right for me?

PERJETA has only been shown to work in people with HER2-positive breast cancer. You must have a HER2 test to know if your breast cancer is HER2-positive before receiving an anti-HER2 treatment, such as PERJETA.

What are the most common side effects?

The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without a fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)


You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or 
www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects.